Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Large Growth in Short Interest

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 26,030,000 shares, an increase of 13.5% from the December 15th total of 22,940,000 shares. Based on an average daily volume of 2,170,000 shares, the days-to-cover ratio is currently 12.0 days.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after acquiring an additional 18,053 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Lineage Cell Therapeutics by 13.9% during the third quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company’s stock valued at $613,000 after purchasing an additional 82,864 shares during the last quarter. Barclays PLC boosted its position in shares of Lineage Cell Therapeutics by 311.3% in the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after purchasing an additional 159,924 shares in the last quarter. Geode Capital Management LLC increased its position in Lineage Cell Therapeutics by 2.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after buying an additional 83,274 shares in the last quarter. Finally, State Street Corp raised its stake in Lineage Cell Therapeutics by 1.8% during the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after buying an additional 45,483 shares during the last quarter. 62.47% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LCTX shares. D. Boral Capital reiterated a “buy” rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. HC Wainwright increased their price target on shares of Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Finally, Maxim Group decreased their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lineage Cell Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $4.80.

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN LCTX opened at $0.59 on Friday. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61. The firm has a market capitalization of $129.47 million, a price-to-earnings ratio of -4.90 and a beta of 1.18.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.